Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 7, 2012; 18(25): 3215-3222
Published online Jul 7, 2012. doi: 10.3748/wjg.v18.i25.3215
Published online Jul 7, 2012. doi: 10.3748/wjg.v18.i25.3215
Table 1 Tumor characteristics according to level of Tsuvmax/Lsuvmean
Tsuvmax/Lsuvmean | Tsuvmax/Lsuvmean | P value | |
< 1.90 (n = 43) | ≥1.90 (n = 40) | ||
Mean age ± SD (yr) | 60 ± 11.7 | 59.9 ± 9.7 | 0.276 |
Sex (male:female) | 34:9 | 34:6 | 0.574 |
Etiology | 0.802 | ||
HBV/HCV/alcohol/others | 35/4/1/3 | 34/5/0/1 | |
Tumor number | 1.8 ± 1.3 | 2.7 ± 1.8 | 0.008 |
Single/multiple | 0.008 | ||
Tumor size (cm) | 5.2 ± 3.2 | 10 ± 5.5 | 0.000 |
< 3 cm | 14 | 1 | 0.000 |
3-5 cm | 11 | 8 | |
> 5 cm | 18 | 31 | |
Portal vein thrombosis | 0.000 | ||
Absent/present | 39/4 | 18/22 | |
Child-Pugh class | 0.758 | ||
A/B | 36/7 | 35/5 | |
Serum AFP (ng/dL) | 2928.5 ± 11573.6 | 35275.2 ± 103428 | 0.011 |
< 400/> 400 | 30/13 | 18/22 | 0.028 |
BCLC stage | 0.000 | ||
A/B/C | 21/13/9 | 7/28/2005 |
Table 2 Tumor characteristics according to objective response
Objective response group(n = 45) | Non-objective response group(n = 38) | P value | |
Mean age ± SD (yr) | 60.8 ± 11.5 | 59.0 ± 9.7 | 0.372 |
Sex (male:female) | 37:8 | 31:7 | 0.940 |
Etiology | 0.555 | ||
HBV/HCV/alcohol/others | 36/5/1/3 | 33/4/0/1 | |
Tumor number | 0.077 | ||
Single/multiple | 25/20 | 13/25 | |
Tumor size (cm) | 4.4 ± 2.3 | 11.2 ± 4.9 | 0.000 |
Portal vein thrombosis | 0.000 | ||
Absent/present | 42/3 | 15/23 | |
Child-Pugh class | 0.756 | ||
A/B | 38/7 | 33/5 | |
Serum AFP | 3795 ± 12054 | 35951 ± 106137 | 0.054 |
BCLC stage | 0.000 | ||
A/B/C | 26/12/7 | 0/8/30 | |
Tsuvmax/Lsuvmea | 0.000 | ||
1.90 </≥ 1.90 | 34/11 | 9/29 |
Table 3 Univariate and multivariate analysis for the factors that influence objective response
P value | ||
Factors | Univariate | Multivariate |
Tumor number single/multiple | 0.077 | 0.357 |
Tumor size (cm) | 0.000 | 0.530 |
Portal vein thrombosis | 0.000 | 0.386 |
Absent/present | ||
BCLC stage | 0.000 | 0.408 |
A/B/C | ||
Tsuvmax/Lsuvmean | 0.000 | 0.020 |
1.90 </≥ 1.90 |
Table 4 Analysis of treatment response according to standardized uptake value ratio by barcelona clinic liver cancer score staging
Treatment response | |||||||
BCLC stage | Tsuvmax/Lsuvmean | CR | PR | SD | PD | Total | P value |
A | < 1.90 | 18 | 3 | 0 | 0 | 21 | 1.0 |
(n = 26) | ≥ 1.90 | 4 | 1 | 0 | 0 | 5 | |
B | < 1.90 | 5 | 3 | 2 | 3 | 13 | 0.048 |
(n = 20) | ≥ 1.90 | 0 | 4 | 3 | 0 | 7 | |
C | < 1.90 | 2 | 4 | 4 | 0 | 10 | 0.000 |
(n = 37) | ≥ 1.90 | 0 | 1 | 11 | 15 | 27 | |
Total | 29 | 16 | 20 | 18 | 83 |
Table 5 Multivariate analysis for the factors that influence overall survival rates
Factors | P value | Exp (B) | 95% CI |
Age | |||
< 60 yr/≥ 60 yr | 0.135 | 0.814 | 0.832-3.955 |
Tumor size | |||
< 3 cm | 0.520 | ||
3-5 cm | 0.456 | 2.420 | 0.269-20.861 |
> 5 cm | 0.519 | 0.689 | 0.237-2.320 |
Tumor number | |||
Single/multiple | 0.079 | 0.413 | 0.154-1.107 |
Portal vein thrombosis | |||
Absent/present | 0.348 | 0.636 | 0.247-1.638 |
BCLC stage | |||
A | 0.032 | ||
B | 0.034 | 0.082 | 0.008-0.824 |
C | 0.053 | 0.314 | 0.097-1.017 |
Tsuvmax/Lsuvmean | |||
1.90 </≥ 1.90 | 0.036 | 0.337 | 0.122-0.932 |
- Citation: Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222
- URL: https://www.wjgnet.com/1007-9327/full/v18/i25/3215.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i25.3215